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Oscillatory  brain  activities  support  many  physiological  functions  from  motor  control  to cognition.  Disrup-
tions  of the  normal  oscillatory  brain  activities  are  commonly  observed  in  neurological  and  psychiatric
disorders  including  epilepsy,  Parkinson’s  disease,  Alzheimer’s  disease,  schizophrenia,  anxiety/trauma-
related  disorders,  major  depressive  disorders,  and  drug  addiction.  Therefore,  these  disorders  can  be
considered  as  common  oscillation  defects  despite  having  distinct  behavioral  manifestations  and  genetic
causes.  Recent  technical  advances  of neuronal  activity  recording  and  analysis  have  allowed  us  to study
the  pathological  oscillations  of  each  disorder  as  a possible  biomarker  of  symptoms.  Furthermore,  recent
advances  in brain  stimulation  technologies  enable  time-  and  space-targeted  interventions  of  the  patho-losed-loop intervention
ranscranial electrical stimulation
euromodulation
pilepsy
sychiatric disorders
scillopathy
logical  oscillations  of both  neurological  disorders  and  psychiatric  disorders  as  possible  targets  for
regulating  their  symptoms.
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c. Introduction: oscillations and neuronal activities are
elf-organized
In contexts of the neuroscience field, oscillations are rhythmic
euronal activities (Buzsáki, 2006). They are typically measured
s fluctuating extracellular potentials by using electroencephalog-
aphy (EEG), electrocorticography (ECoG), intracranial local field
otential (LFP) or read out with functional brain imaging tech-
iques or magnetoencephalography (MEG) each offering different
ime and spatial resolutions (Hong and Lieber, 2019). The major
ource of oscillations is rhythmically synchronizing synaptic
ransmissions. The rhythmicity stems from network structures
omposed of distinct cell-types and the population activities inside
he network (Buzsáki et al., 2012). For example, at mesoscopic
etwork levels, inhibitory neurons are essential to generate oscil-
atory network activities; the interactions of excitatory pyramidal
nd inhibitory basket neurons via their reciprocal connections
enerate gamma  band oscillations and sharp wave-ripples in the
ippocampus (HPC) (Buzsáki and Watson, 2012; Stark et al., 2014).
t macroscopic network levels (the interaction between brain
egions), the medial septum (MS, a rhythmogenic basal forebrain
ucleus) externally regulates theta band oscillations in the HPC
Kang et al., 2017). Emergent oscillations (the extracellular electri-
al field) then orchestrates neuronal activities (the ephaptic effects)(Anastassiou et al., 2011). Thus, oscillations and neuronal activi-
ties in the brain are interdependent and self-organized. Oscillations
reflect functional network states, and they affect neuronal popula-
tion activities in the network.
Many studies have revealed that oscillatory brain activities sup-
port various brain functions such as motor control and cognition
including spatial memory (Girardeau et al., 2009), arbitrary rep-
resentational spaces (Agarwal et al., 2014; Solomon et al., 2019),
sleep (Watson and Buzsáki, 2015), and emotions (Karalis et al.,
2016; Likhtik et al., 2014) via temporally coordinated interactions
between multiple brain regions (Bonnefond et al., 2017). Therefore,
if oscillations are disrupted (and the neuronal activity is conse-
quently disrupted), normal brain functions are supposed to be
disrupted. If oscillations reflect both normal and pathological brain
states, they could be good biomarkers of symptoms or behavioral
phenotypes of neurological and psychiatric disorders. Oscillations
are the dynamics of macroscopic neuronal circuits, which is the
closest to the behavioural phenotypes in the multiple levels of
biological structure (Fig. 1) (Leuchter et al., 2015). Thus, it is not
surprising that more-and-more studies show the coincidence of
the temporal expression of pathological oscillations with that of the
abnormal behavioral phenotypes of neurological and psychological
disorders (see Section 2); these disorders are considered as ‘Oscil-
lopathies’ (Mathalon and Sohal, 2015). Pathological oscillations
Y. Takeuchi, A. Berényi / Neuroscience
Fig. 1. The concept of oscillotherapeutics.
A behavior is generated as a result of brain dynamics. Brain dynamics are deter-
mined by factors at various levels from genes to macroscopic network activity as a
hierarchical system. The macroscopic circuit level is the closest to the behavior level.
Therefore, oscillation (which reflects the dynamics of the macroscopic circuit level)
supposes to have a close temporal correlation to (and an evident causal relationship
to) behavioral phenotypes. There are huge variations at both the gene and subcel-
lular levels of neurological and psychiatric disorders. In contrast, variations in the
phenomenology of neurological and psychiatric disorders at the macroscopic circuit
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2evel (oscillation) are relatively minor. Therefore, time-targeted pathological oscil-
ation intervention for neurological and psychiatric disorders (oscillotherapeutics)
ould be an effective strategy for regulating their behavioral phenotypes.
ossibly come with both a correlation and a causal relationship
ith abnormal brain states and functions. If this is the case, the
athological oscillations may  be a therapeutic intervention or mod-
lation target for the disorders using the recently emerged time-
nd space-targeted brain stimulation technologies (Berényi et al.,
012; Vöröslakos et al., 2018). We  call this strategy ‘Oscillothera-
eutics’.
In the following sections, we provide overviews on 1) the
henomenology of oscillopathies, 2) how we find abnormality in
scillations in animal models and human subjects, 3) how patho-
ogical oscillatory states emerge mechanically, a strategy for its
ntervention, 4) the embodiments of oscillotherapeutics in distinct
timulation modalities, and 5) the engineering challenges of future
linical applications of oscillotherapeutics.
. Oscillopathy – a phenomenological overview
Oscillopathy is defined as a neurological or psychiatric disor-
er in which abnormality in oscillatory brain activities is observed
Braun et al., 2018; Buzsáki and Watson, 2012; Mathalon and Sohal,
015). We  will briefly summarize abnormal oscillations of known
scillopathies which can be targeted by interventions.
.1. Epilepsy
Epilepsy is a neurological disorder characterized by an enduring
redisposition to generate epileptic seizures (Fisher et al., 2014).
n epileptic seizure is a transient behavioral change that might
arry objective, overtsigns (e.g. convulsions) or subjective, covert
ymptoms (e.g. loss of consciousness). These changes are most
robably caused by abnormally synchronous neuronal activities
n the brain. The synchronized neuronal activity is quite evident
n EEG measurements during seizures (ictal period) and the EEG
ynchronization is concomitant with behavioural manifestations
uch as tonic and clonic convulsions. Successful pharmaceutical
nd surgical treatments of epilepsy consistently reduce the fre-
uency of electrographic and behavioural seizures (Glauser et al.,
006; Li and Cook, 2018). Furthermore, time-targeted interven- Research 152 (2020) 87–107 89
tion with the pathological neuronal oscillations of seizures or
seizure predictions suppresses the behavioural manifestation of
seizures (Morrell, 2011). This strongly suggests a causal relation-
ship between the pathological oscillation of EEG measurements and
the symptoms of epilepsy. Thus, epilepsy is a typical oscillopathy.
2.2. Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disease charac-
terized by tremor, rigidity, bradykinesia, and postural instability
with the underlying loss of nigrostriatal dopaminergic neurons
(Soileau and Chou, 2016). The pathological hallmark of PD is
the finding of protein aggregates containing -synuclein in neu-
rons called Lewy bodies throughout brain. Symptoms of PD are
thought to be caused by the dysfunction of the corticostriatal-
thalamocortical (CSTC) loop due to decreased dopaminergic tone.
Dopamine replacement therapy (DRT) is typically used to ame-
liorate the associated motor disturbances. There are pathological
oscillations of tremor (4–7 Hz), double tremor (10 Hz), and beta
(15–30 Hz) frequencies in the CSTC loop of PD patients (Holt et al.,
2019; Weinberger et al., 2009) and animal models (Deffains and
Bergman, 2019; Heimer et al., 2006). Disruption of pathological
oscillations by DRT (Heimer et al., 2006), the inactivation of the
subthalamic nucleus (STN) (Wichmann et al., 1994), or deep brain
stimulation (DBS) of the STN (Deuschl et al., 2006) consistently
decreases the motor disturbances of PD. This suggests a causal rela-
tionship between the pathological oscillations and symptoms of
PD (Bergman et al., 2015). The target of the STN stimulation may
be the corticostriatal axons (Gradinaru et al., 2009). The intrinsic,
slowly oscillating resting network activity, measurable by fMRI, is
called default mode network (DMN) (Raichle, 2015). This network
mostly consists of hub-like brain structures including the medial
prefrontal cortex (PFC), the precuneus, and the posterior cingulate
cortex (Hagmann et al., 2008). In PD patients, there are PD spe-
cific changes in the DMN  (Delaveau et al., 2010; van Eimeren et al.,
2009). These changes were restored by DRT (Delaveau et al., 2010)
and possibly will also be restored by DBS in the future (Kringelbach
et al., 2011).
2.3. Alzheimer’s disease
Alzheimer’s disease (AD) is a chronic neurodegenerative dis-
ease characterized by well-defined neurological features: neuronal
loss, neurofibrillary tangle, and senile plaque. However, the clini-
cal manifestations of AD as a major neurocognitive disorder are
mainly psychiatric which include dementia, paranoia, depression
and other cognitive defects: the Diagnostic and Statistical Man-
ual of Mental Disorders (DSM-5) (American Psychiatric Association,
2013).
Oscillopathic endophenotypes of AD are explored mainly phe-
nomenologically yet, and are summarized below (Cassani et al.,
2018): (1) Slowing. The power spectrum shifts from high-frequency
components (alpha, beta, and gamma) toward low-frequency
components (delta and theta) that are commonly seen in the
resting-state EEG measurements of AD patients (Jeong, 2004). This
shift is proportional to the progression of AD and is thought to
appear due to the decrease of cholinergic tones. (2) Reduced com-
plexity. A decrease in the complexity of the brain electrical activity
has been observed in AD patients (Jeong, 2004). (3) Decrease
in synchronization. Synchronization between brain regions in
AD patients decreases (Babiloni et al., 2016; Wen  et al., 2015).
The synchronization was evaluated using the Pearson correla-
tion coefficient, magnitude coherence, phase coherence, Granger
causality, phase synchrony, global field synchrony, and cross-
frequency coupling. (4) Long-range, effective EEG connectivity
(functional coupling) decreases (e.g. front-parietal, front-temporal)
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Babiloni et al., 2016). (5) The disruption of delta waves during
low wave sleep (Zott et al., 2018). These oscillopathic features
ere also reported with MEG  and fMRI studies (Engels et al.,
017; Greicius, 2008). Amyloid-beta and tau protein pathologies
re at least partially causal to these oscillopathic features of AD
ecause amyloid-beta peptides and tau proteins affect excitatory
nd inhibitory synaptic transmissions and thereby memory func-
ions in a concentration dependent manner (Gulisano et al., 2019;
oberson and Mucke, 2006). Amyloid-beta peptides are known
o disrupt the excitatory/inhibitory balance by interfering with
ABAergic interneurons as well (Mably and Colgin, 2018).
Furthermore, acute application of soluble amyloid-beta alone
an acutely and reversibly disrupt synchronizing slow waves across
he cortex, thalamus and HPC during non-rapid eye movement
REM) sleep-like anaesthetized mice (Zott et al., 2018). The reduc-
ion in gamma oscillations in AD animal models is commonly
bserved (Mably and Colgin, 2018). Inversely, the artificial induc-
ion of gamma oscillations in the brain decreases amyloid-beta
epositions, prevents neuronal loss, and improves cognitive func-
ions in AD animal models (Adaikkan et al., 2019; Iaccarino et al.,
016; Martorell et al., 2019). The introduction of high-frequency
scillatory activity into the brain via fornix DBS decreases amyloid-
eta deposition in a rat AD model (Leplus et al., 2019) and
mproves cognitive functions in both AD animal models and
atients (Mirzadeh et al., 2016).
.4. Schizophrenia
Schizophrenia is a severe psychiatric illness characterized by
ositive symptoms including delusions, hallucinations, or para-
oia, and negative symptoms including a loss of motivation, apathy,
social behavior, loss of affect, and poor use and understanding
f speech. Schizophrenia patients also have cognitive symptoms
uch as impaired working memory, dissociated thought processes,
nd impaired executive function (Sontheimer, 2015). Because of
n absence of unequivocal biomarkers, schizophrenia is diagnosed
ntirely on the assessment of symptoms by a trained psychi-
tric doctor who bases his or her judgment on a number of
eatures described in DSM-5 (American Psychiatric Association,
013). Therefore, efforts have been made to find an appropriate
iomarker using functional brain imaging techniques, EEG and MEG
ecordings etc. (Meyer-Lindenberg, 2010). For example, fMRI stud-
es revealed that PFC activity was reduced in schizophrenia patients
Barch et al., 2001); the PFC governs executive function, task initia-
ion, motivational drive, and working memory. Reduced activities
ave been reported on the amygdala (AMY) and the HPC (Meyer-
indenberg, 2010), which could explain the flat affect of individuals
f schizophrenia. Resting state networks have also been changed in
chizophrenia patients (Alexander-Bloch et al., 2012; Cabral et al.,
012).
Gamma  oscillations typically result from the fast, reciprocal
nteractions of excitatory glutamatergic neurons and inhibitory
ABAergic neurons in the brain (Buzsáki and Wang, 2012). These
scillations are thought to support many cognitive functions
ncluding working memory in the PFC (Benchenane et al., 2011;
oux and Uhlhaas, 2014). Studies have found that gamma  oscilla-
ions were disrupted in schizophrenia patients (Gonzalez-Burgos
t al., 2015; Senkowski and Gallinat, 2015) and that this gamma
isruption in the PFC presumably leads to disrupted intra-PFC and
FC-HPC communications (Moran and Hong, 2011). The decreased
amma  oscillations are mediated by hypofunctional GABAergic
etworks in the PFC (Lewis et al., 2012). This finding is sup-
orted by evidence that the gene expression of 67-kD isoform of
lutamic acid decarboxylase, the key enzyme in GABA synthesis,
s reduced in the post-mortem brains of schizophrenia patients
Akbarian et al., 1995; Volk et al., 2000). It has been reportede Research 152 (2020) 87–107
that repeated transcranial magnetic stimulation (rTMS) of the dor-
solateral prefrontal cortex (DLPFC) restored gamma oscillations
of schizophrenia patients and cognitive functions concomitantly
(Farzan et al., 2012). This result suggests a possible causal rela-
tionship between the reduction in frontal gamma  oscillation and
cognitive deficit in schizophrenia (Pittman-Polletta et al., 2015).
2.5. Anxiety and trauma-related disorders
Generalized anxiety disorder (GAD) and post-traumatic stress
disorders (PTSD) are characterized by chronic and exaggerated
anxiety and fear (American Psychiatric Association, 2013). Concep-
tually, these disorders can be related to (1) the overgeneralization
of perception, interpretation, and assessment of innocuous stimuli
and (2) overexpression of anxiety and fear responses. The former is
explained by the disruption of the PFC, pattern separation of the
HPC, and intrinsic sensory hyperactivity in the primary sensory
cortex. For example, resting EEG recordings from PTSD patients
revealed that there was disrupted sensory processing with intrin-
sic sensory hyperactivity in the visual cortex (suppressed alpha
power), decreased bottom-up alpha power-mediated inhibition to
the frontal cortex, and increased frontal gamma band (30–50 Hz)
power activated by the intrinsic sensation (Clancy et al., 2017). The
latter can be explained by enhanced neural activity in the negative
emotion networks. For example, Huang et al. (2014) found hyper-
activities in the AMY, the HPC, and the insular cortex in resting
MEG  recordings of PTSD patients, which are supposed to positively
correlate with their symptoms.
In addition, Qiao et al. (2017) found stronger functional con-
nectivity with the AMY, insular cortex, putamen, thalamus, and
posterior cingulate cortex (which are negative emotion circuits)
in resting state fMRI recordings of GAD patients. In contrast, they
found that weaker connections in the frontal and temporal cor-
tices in GAD patients. Interestingly, they also found decreased
effective connectivity (Granger causality) from the frontal cortexes
to the AMY  and basal ganglia (Qiao et al., 2017), which is the
top-down inhibitory activity control of the subcortical networks.
The MEG  study also reported that the alpha (8–12 Hz) activity of
PTSD patients decreased in the DLPFC and ventromedial PFC, and
it also decreased the top-down alpha causality from these struc-
tures (Huang et al., 2014). Other resting state EEG studies support
hypofunction of the frontal cortexes in GAD and PTSD patients
(Crost et al., 2008; Eidelman-Rothman et al., 2016; Veltmeyer et al.,
2006). Rodent studies have shown the role of the PFC in regulat-
ing the limbic system as a top-down control of fear expression and
anxiety, which are mediated by theta or alpha range functional cou-
plings (Dejean et al., 2016; Karalis et al., 2016; Likhtik et al., 2014).
Therefore, on-demand modulation of the top-down control may  be
effective for supressing excessive anxiety and fear expression.
2.6. Major depressive disorder
Major depressive disorder (MDD) is a common and persistent
psychiatric disorder characterized by extreme feelings of sadness
and low mood disproportionate to any possible cause (American
Psychiatric Association, 2013). MDD  results in tremendous soci-
etal costs (Greenberg et al., 2003). Intracranial electrophysiological
recordings from epilepsy patients indicate that mood can be
decoded from multi-channel LFP recordings in the limbic system,
including the orbitofrontal cortex, the cingulate cortex, the AMY,
the HPC, the superior frontal cortex, and the middle frontal cortex
(Reardon, 2017; Sani et al., 2018). Vulnerability to stress and sus-
ceptibility to depression have been decoded from multi-channel
recordings in the limbic system in animal models of depression
(Hultman et al., 2016, 2018). These models indicate the oscillo-
pathic nature of depression.
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The oscillopathic features of MDD  are summarized as follows
Baskaran et al., 2012; Eidelman-Rothman et al., 2016; Fitzgerald
nd Watson, 2018): (1) elevated alpha band activity in the tem-
oroparietal region; (2) elevated frontal theta band activity; (3)
lpha frontal asymmetry (left hemispheric hypoactivity and right
emispheric hyperactivity represented as alpha, theta, and beta
and activities); and (4) decreased gamma  band activity. These
eatures relate to MDD  symptoms and predict the effective-
ess of pharmacological treatment using tricyclic antidepressants
nd selective serotonin reuptake inhibitors and electroconvulsive
herapy (ECT). This suggests their usefulness as a biomarker of
epression disorder. In addition, fMRI studies suggest that the
MN, the cognitive control network, and the affective network
ere functionally hyperconnected in depression patients (Sheline
t al., 2010). Functional decoupling of these networks by neu-
omodulation techniques may  relieve depression symptoms (Fox
t al., 2012; Liston et al., 2014).
Furthermore, there may  be causal relationships between oscil-
ation disturbances and depression symptoms. First, restoration of
he frontal alpha symmetry using anodal transcranial direct current
timulation (tDCS) on the DLPFC (Loo et al., 2012) and specifically
eurofeedback (Mennella et al., 2017) improved depression symp-
oms. In addition, subanaesthetic dose of ketamine (0.5 mg/kg)
educed delta oscillations (1–5 Hz) and increased gamma  oscilla-
ions (45–85 Hz) in the human cortex and improved depressive
ode of patients (Berman et al., 2000; Hong et al., 2010). Further-
ore, high frequency rTMS on the left DLPFC increased resting
tate gamma oscillations in the frontal cortex and improved the
epressed mood in patients (Noda et al., 2017). These pathologi-
al oscillations can be targeted using molecular (pharmacological),
etwork (neuromodulation), and cognitive (behavioural) methods
o interrogate depression symptoms (Leuchter et al., 2015).
.7. Drug addiction
Drug addiction (also known as substance use disorder) is a
hronically relapsing disorder characterized by persistent drug
eeking and drug-taking behaviors despite significant negative
hysical, emotional, social and occupational consequences (Volkow
nd Morales, 2015). Drug addiction progresses from an impulsive
o a compulsive intake in a collapsed cycle that consists of three
tages: (1) preoccupation/anticipation, (2) binge/intoxication, and
3) withdrawal/negative affect (Koob and Volkow, 2010). At the
eginning, the voluntary or impulsive intake induces euphoria
uring the binge/intoxication stage and positive reinforcement
ill drive the next intake. After establishment of maladaptation
addicted state), negative reinforcement caused by relief of anxiety,
tress, and/or restlessness during abstinence will be a drive for fur-
her intake (Volkow et al., 2016). In the preoccupation/anticipation
tage, patients have a craving, and obsession to get drugs.
In addicted brains, many neuroadaptations happen from epige-
etic to neurocircuit levels. These neuroadaptations contribute to
hronic, obsessive drug intake behaviors and impulsive decision-
aking in the preoccupation/anticipation stage. For example, the
eural activity of the PFC is reduced (hypofrontality) in addicted
atients (e.g. smokers) (Goldstein and Volkow, 2011; Zilverstand
t al., 2018). This reduced activity would presumably be a cause
f impulsive decision-making of addicted patients (Bechara, 2005)
ecause the PFC governs analysis, prediction, and the executive
ontrol of reward seeking behaviors (Kennerley and Walton, 2011).
Abnormal frontal EEG measurements during the resting state
re also observed in opioid users (Motlagh et al., 2017), alcohol
busers (Huang et al., 2018), tobacco smokers (Li et al., 2017),
annabis users (Prashad et al., 2018), and psychostimulant users
Newton et al., 2003), although their abnormalities are dependent
n drug modalities (Newson and Thiagarajan, 2019). The oscillation Research 152 (2020) 87–107 91
abnormality in the frontal cortex is context dependent as well. For
example, frontal asymmetry (left lateralization effects, less alpha
oscillation in the left hemisphere) occurred in cocaine abusers in
response to losing on their choice of immediate large rewards dur-
ing the Iowa gambling task (Balconi et al., 2014). These disrupted
frontal oscillatory activities are also represented by the reduction
of the top-down inhibitory control called the executive control net-
work (ECN), which for example controls the desire salience for
drugs (Bechara, 2005). Together with the DMN  and the salience net-
work, the decreased ECN activity is a good predictor of the cravings
of chronic tobacco smokers (Lerman et al., 2014; Sutherland et al.,
2012). The restoration of the ECN by rTMS of the left DLPFC alle-
viated nicotine craving with significant EEG power changes (Pripfl
et al., 2014).
Therefore, an obsessive drug taking habit driven by drug
craving and impulsive decision-making during the preoccupa-
tion/anticipation stage may  be treated with non-invasive or
invasive stimulation (Dandekar et al., 2018; Diana et al., 2017), or
cognitive interventions (Zilverstand et al., 2016) by modulating the
oscillating networks where the PFC is central. Negative reinforce-
ment during the withdrawal/negative affect stage (which can be
mediated by delta and gamma  band activities in the limbic sys-
tem including the PFC and the nucleus accumbens (NAc) (Dejean
et al., 2013, 2017)) may  be intervened by DBS or non-invasive stim-
ulation (Dandekar et al., 2018; Diana et al., 2017). Positive valence
during the binge/intoxication stage (which is presumably mediated
by delta-band activity in the NAc (Wu  et al., 2018)) may be replaced
by DBS of the NAc or the medial forebrain bundle (Dandekar et al.,
2018). These facts indicate the oscillopathic features of drug addic-
tion and the possible applications of oscillotherapeutics.
3. Mapping of oscillopathies
Appropriate animal models for each disease or disorder are
required to facilitate development of oscillotherapeutics. Appro-
priate recording techniques for the oscillating neuronal activities
of animal models and humans are indispensable, as are efficient
analytical methods. Thus, here we provide an overview of how the
pathological oscillations of neurological and psychiatric disorders
are recorded and detected (the ‘diagnostic’ in research and clinics).
3.1. Animal models
3.1.1. Animal models for epilepsy
Animal models for epilepsy research are thoroughly summa-
rized in the book of Pitka¨nen et al. (2017). Briefly, the epilepsy
models are classified by seizure types (generalized or focal, petit
mal  or grand mal), animal species (mice, rats, cats etc.), whether
in vitro or in vivo, whether genetic or acquired, whether acute or
chronic, and how each seizure is evoked (electrical, chemical, sen-
sory inputs, spontaneous etc.).
Chronic spontaneous seizure models are typically employed
for the development of time-targeted closed-loop interventions.
Tottering (tg) and Stargazer (stg) mouse strains are available to
study absence (petit mal) seizures with spike-and-wave discharges.
These strains have known mutation on alpha and gamma sub-
units of voltage-dependent calcium channels, respectively (Upton
and Stratton, 2003). Two inbred strains are for example avail-
able for rat experiments: the genetic absence epilepsy rats from
Strasbourg (GAERS) and the Wistar Albino Glaxo strain (WAG/Rij)
(Coenen and van Luijtelaar, 2003; Danober et al., 1998). The spike-
and-wave discharges are seen in ordinal outbred laboratory rats
and even in wild-caught rats as well (Taylor et al., 2019). Absence
seizures can induced acutely by systemic administration of a single
pharmacological compound [4,5,6,7 tetrahydroxyisoxazolo (4,5,c)
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yridine 3-ol (THIP), low dose pentylenetetrazole (PTZ), or gamma-
ydroxybutyrate] in rats (Fariello and Golden, 1987; Marescaux
t al., 1984; Snead, 1988) and chronically by prepuberty sys-
emic administration of AY-9944 or methylazoxymethanol acetate
MAM)-AY in rats (Cortez et al., 2002; Serbanescu et al., 2004).
The systemic injection of GABAA receptor antagonists (e.g. PTZ,
icuculline, picrotoxin) can induce acute generalized convulsion
eizures in rodents (Mackenzie et al., 2002; Velisek et al., 1992;
elísˇková et al., 1991). The systemic injection of glutamate recep-
or agonists (e.g. kainic acid and NMDA) or muscarinic receptor
gonists (e.g. pilocarpine) can also induce acute, generalized, con-
ulsive seizures in rodents (Ben-Ari et al., 1981; Maresˇ and Velisˇek,
992; Turski et al., 1983). In addition, the inhalation of flurothyl can
e used (Prichard et al., 1969), along with intracranial injections of
icuculline, picrotoxin, kainic acid and other drugs to induce acute
onvulsive seizures in rodents (Ben-Ari et al., 1980; Sierra-Paredes
nd Sierra-Marcun˜o, 1996; Velísˇková et al., 1991). A chronic sponta-
eous, limbic seizure rodent model can be prepared by the repeated
ystemic injection of PTZ, kainic acid, or pilocarpine (Cain, 1981;
avalheiro et al., 1991; Hellier et al., 1998), a single intrahippocam-
al injection of kainic acid (Bragin et al., 1999), or repeated daily
lectrical stimulation of the limbic structure (e.g. the AMY, HPC)
Goddard et al., 1969; McIntyre and Gilby, 2009). Genetic models
or spontaneous convulsive seizures are available both in mouse
nd rat strains (e.g. weaver mice, NER/Kyo rats) (Serikawa et al.,
015; Upton and Stratton, 2003). Auditory stimulation can induce-
onvulsive seizures in the generically epilepsy-prone rats (GEPRs)
nd DBA/2 mice (De Sarro et al., 2017).
.1.2. Animal models for Parkinson’s disease
Animal models of PD are classified into neurotoxin models
nd genetic models (Gubellini and Kachidian, 2015). 6-OHDA
6-hydroxydopamine) and MPTP (1-methyl-4-phenyl-1,2,3,6-
etrahydropyridine) are typically used to mimic  selective loss of
igrostriatal dopaminergic neurons via mechanism by which mito-
hondrial complex I is blocked (Tieu, 2011). Both neurotoxins are
sed in rodent and non-human primate experiments.
Systemically administered MPTP can easily cross the blood brain
arrier whereas 6-OHDA should be stereotaxically injected into
he target brain structure (usually the substantia nigra pars com-
acta (SNc), the medial forebrain bundle, or the striatum). 6-OHDA
nd MPTP administrations lead to significant PD-like motor symp-
oms including akinesia, freezing, bradykinesia, muscle rigidity,
bnormal posture, stereotypy and tremor associated with signif-
cant degenerative loss of SNc dopaminergic neurons (Smeyne and
ackson-Lewis, 2005). Neither 6-OHDA nor MPTP administration
nduces Lewy body-like inclusions with alpha-synuclein (Cenci
t al., 2002). Importantly, both the 6-OHDA rodent model and the
PTP-treated monkeys exhibit pathological oscillations in their
asal ganglia as frequently observed in human patients: tremor
4–7 Hz), double tremor (10 Hz), and beta (15–30 Hz) (Deffains and
ergman, 2019; Heimer et al., 2006). Mutations of causal genes or
enetic risk factors of Parkinson’s disease are modelled in mice and
ats including SNCA (alpha-synuclein), PRKN (parkin), PINK1 (PTEN-
nduced putative kinase 1), DJ-1 (PARK7) and LRRK2 (leucine-rich
epeat kinase 2). These models offer ways to study pathology as
ewy-body like inclusions, but they exhibit only mild motor symp-
oms. Pathological oscillations in the basal ganglia in these genetic
odels have not been studied well yet.
.1.3. Animal models for Alzheimer’s disease
Most AD patients are sporadic and there are some animal modelsor sporadic AD using metabolic and traumatic brain injury-induce
amage etc. (Zhang et al., 2019). However, the vast majority of
urrent AD animal models are transgenic rodents (mainly mice)
nd are based on the amyloid and tau hypotheses, and the genet-e Research 152 (2020) 87–107
ics of the familial form of the disease (Mullane and Williams, 2019).
Nearly 170 transgenic/knock-in/knock-out models of AD have been
developed to date (ALZ FORUM Research Models Database; https://
www.alzforum.org/research-models). They are principally focused
on mutations in APP (Amyloid precursor protein), PSEN1 (prese-
nilin 1), MAPT (microtubule-associated protein tau), and Trem2
(Triggering receptor expressed on myeloid cells 2), and APOE
(apolipoprotein E), as well as the transfection of the amyloid
processing enzyme, BACE1 (Beta-Secretase 1) (Götz et al., 2018;
Mullane and Williams, 2019). The model animals have single or
multiple mutations of these genes. For example, 3×Tg mice, which
have APP KM670671NL (Swedish), MARPT P301 L, and PSEN1 M146
V triple mutations, show amyloid beta plaque, hyperphosphory-
lated tau, and neurofibrillary tangle as pathological phenotypes and
deficits in working, spatial, and fear conditioning memory (Oddo
et al., 2003). 5 × FAD mice have three mutations on APP (Swedish,
Florida, London) and two  mutations on PSEN1,  and they show
amyloid-beta plaque and memory deficits as soon as two months
old (Oakley et al., 2006). In the tau pathology model, rTg4510 mice
with MAPT P301 L mutation have neurofibrillary tangle, neuronal
loss and memory deficits as phenotypes (Santacruz et al., 2005).
The overexpression of mutant human APOE4 protein (a risk factor
of AD) in APOE4-KI mice results in significant memory impairment
as well (Sullivan et al., 2004).
Importantly, all these AD models (3×Tg, 5 × FAD, rTg4510,
APOE4-KI) consistently show a reduction of slow gamma oscillation
in the CA1 of HPC (Booth et al., 2016; Gillespie et al., 2016; Iaccarino
et al., 2016; Mably et al., 2017), which contributes to the encoding
and retrieval of memory. CA1 place cell representations of space
were unstable in these mice and the deficits in slow oscillations
in the HPC were concomitant with spatial memory. Surprisingly,
the optogenetic activation of parvalbumine (PV)-interneurons at
slow gamma  frequencies (or 40 Hz light flicker sensory stimula-
tion) reduced amyloid-beta depositions in the brain and restored
cognitive impairment of the AD mice model (Iaccarino et al., 2016;
Martorell et al., 2019).
In the APP23 × PS45 mouse model (Busche et al., 2008),
the coherence of slow waves between different cortical regions,
the thalamus, and the HPC is completely disrupted in the light
anesthesia condition (Zott et al., 2018). This resembles dis-
rupted, slow-wave oscillations during natural non-REM sleep in AD
patients (Winer et al., 2019). The coherent slow wave oscillations
were transiently disrupted in wild-type mice by the applica-
tion of soluble amyloid-beta, which suggests a causal relationship
between amyloid-beta and the pathological oscillation pattern in
AD (Busche et al., 2015).
3.1.4. Animal models for schizophrenia
Animal models of schizophrenia mostly fit into one of four dif-
ferent induction categories: developmental, drug-induced, lesion
or genetic manipulation models (Jones et al., 2011). Examples of
neurodevelopmental models include gestational MAM  injections,
bacterial or viral infections, and post-weaning social isolation;
pharmacological models include amphetamine-induced psychosis,
NMDA antagonist [phencyclidine (PCP), MK-801, ketamine)]-
induced psychosis; lesion models include neonatal ventral HPC
lesion; genetic models include various knock-out or mutant models
of schizophrenia susceptibility genes, some of which were vali-
dated by genome-wide association studies (Schizophrenia Working
Group of the Psychiatric Genomics Consortium, 2014).
These models resemble various cognitive symptoms found in
schizophrenia patients including deficits of sensorimotor gating,
working memory, visio-spatial memory, and object recognition,
as well as decreased social interaction, increased locomotion, and
exaggerated sensation etc. The models also show cellular or cir-
cuit level alterations including decreased synaptic connections,
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nd spine densities, the loss of prefrontal PV-positive interneu-
ons, the loss of dendrites in cortical pyramidal neurons, and
athological oscillations (e.g. dysfunctional prefrontal gamma
scillations). The pathological oscillations tie the cellular or cir-
uit level pathophysiology to alterations in local processing and
arge-scale coordination, and in turn may  lead to cognitive and per-
eptual disturbances observed in schizophrenia (Pittman-Polletta
t al., 2015; Senkowski and Gallinat, 2015).
A number of schizophrenia-susceptibility genes have been
dentified on chromosome 22. These include DISC1 (disrupted-
n-schizophrenia 1), NRG1 (neuregulin 1) and its receptor ERBB4
erb-b2 receptor tyrosine kinase 4, erbB-4), and COMT (catechol-
-methyltransferase). DISC1 is a synaptic protein that plays a
rucial role in synaptogenesis (Bennett AO, 2008). Mutations or
he functional disturbance of DISC1 lead to the disruption of PV-
ositive interneuron cytoarchitecture and hypofunction in the
ortex and HPC, which is critical for normal oscillatory activity in
he brain (Koyama et al., 2013; Nakai et al., 2014). NRG1 and ERBB4
re also synaptogenic schizophrenia susceptible genes (Mei  and
iong, 2008). Their disruption resulted in abnormal gamma  oscil-
ations in the HPC and disrupted functional coupling between the
entral HPC and NAc (Koyama et al., 2013; Nason et al., 2011).
educed dysbindin-1 (another synaptic protein from suscepti-
le gene DTNBP1 (Dickman and Davis, 2009)) is associated with
educed phasic activation of PV-positive interneurons and reduced
amma  oscillations (Carlson et al., 2011).
One of the largest risk factors for schizophrenia is the microdele-
ion of chromosome 22q11.2 that wipes out up to 60 genes;
he 22q11.2 deletion syndrome results in facial abnormalities,
eart defects, and a number of neuropsychiatric conditions (Jonas
t al., 2014). A quarter of the patients that have the microdele-
ion of this chromosome develop schizophrenia. Importantly,
n the Df(16)A+/− mouse model of this micro delision, mice
xhibited reduced PFC-HPC synchrony, represented by reduced
hase-locking of PFC neurons to HPC theta oscillation and disrupted
oherence across multiple frequency ranges (delta to gamma
anges) (Sigurdsson et al., 2010).
As pharmacological models, NMDA receptor blockers such as
etamine and PCP are known to induce delusions and hallucina-
ions in otherwise healthy subjects (Krystal et al., 1994). Ketamine
s known to attenuate both background and sensory evoked theta
ower in the CA3 in mice. It enhances both background and evoked
amma  power, but it decreases relative-induced gamma  power
Lazarewicz et al., 2010). This suggests that ketamine decreases
he signal-to-noise ratio of gamma-band activity and possibly leads
o disrupted pattern separation function in the CA3 region, con-
ributing its dissociative feeling. Ketamine reduces NMDA receptor
unction preferentially on PV-positive interneurons, which impairs
PC synchrony, spatial representations, and working memory in
ice (Korotkova et al., 2010). The NMDA hypofunction also reduces
elta and theta activity in the cortex and HPC (Kiss et al., 2013).
etamine also disrupts the theta modulation of gamma-band activ-
ty and reduces network responsibility to the environment in a
omputer model of HPC (Neymotin et al., 2011).
As a gene-environment interaction model, WISKET rats were
eported as a selectively bred line with schizophrenia-like phe-
otypes (reduced sensorimotor gating, hyperalgesia, and memory
eficit) after post-weaning social isolation and chronic ketamine
reatment over 15 generations (Büki et al., 2018). The WISKET
ats showed increased theta, alpha, and beta-band activities and
educed gamma-band activities in ECoG recordings (Horvath et al.,
016)..1.5. Animal models for anxiety and trauma-related disorders
Animal models for anxiety and trauma-related disorders are
lassified into five models: experience-based, pharmacologic, phar- Research 152 (2020) 87–107 93
macological lesion, selectively bred genetic, and specific transgenic
(Hoffman, 2016). Examples of experience-based models include
fear conditioning and extinction, pre-weaning stress, and mater-
nal deprivation. Pharmacologic models include yohimbine (alpha-2
adrenergic receptor antagonist), CCK tetrapeptide (CCK-4, an anx-
iogenic neuropeptide), caffeine (adenosine receptor antagonist),
m-chlorophenylpiperazine (serotonin 5-HT2C receptor antago-
nist), and FG7142 (benzodiazepine partial inverse antagonist).
Pharmacological lesion models include the chronic infusion of l-
allylglycine (an inhibitor of glutamic acid decarboxylase) into the
dorsomedial/perifornical region of the hypothalamus (DMH/PeF) in
rats (Johnson and Shekhar, 2012). Selectively bred genetic models
include Roman High and Low Avoidance rats (Escorihuela et al.,
1999), Sardinian alcohol-preferring rats (Colombo et al., 1995),
High anxiety behavior and Low anxiety behavior rats (Yilmazer-
Hanke et al., 2004), Floripa H and L rats (Ramos et al., 2003),
Ultrasonic rats (Brunelli and Hofer, 2007), and High anxiety behav-
ior mice (Erhardt et al., 2011). Specific transgenic models include
5-HT transporter knockout mice, brain-derived neurotrophic fac-
tor (BDNF) Val66Met mice, COMT and monoamine oxidase A
deficient mice, 5-HT1A knockout mice, corticotropin-releasing
hormone overexpression mice, and neuropeptide Y-knockout
mice.
Their endophenotypes can be measured as startle reactivity,
behavioral inhibition (via the open field and elevated plus mazes,
as well as the light/dark, social interaction, and punished con-
flict tests), carbon dioxide sensitivity (avoidance of a CO2-enriched
environment, exploratory behavior after exposure to CO2-enriched
air, tidal respiratory volume during exposure to CO2-enriched air),
and fear over-generalization (discrimination of CS+ and CS− stimuli
after fear conditioning). Recent studies have revealed that distinct
oscillatory activities in specific PFC-AMY-HPC networks are related
to both fear/anxiety expression and its regulations (C¸ alıs¸ kan and
Stork, 2019; Dejean et al., 2016; Karalis et al., 2016; Likhtik et al.,
2014).
3.1.6. Animal models for depressive disorders
Animal models for depressive disorders are classified into five
models: experience-based, pharmacologic, lesion, genetic, and
gene-environment interaction (Hoffman, 2016). Experience-based
models include learned helplessness, chronic adult stress (e.g.
overnight illumination, water or food restriction, tilting cages,
social isolation or crowding etc.), early life stress (e.g. mater-
nal separation), and social stress (e.g. chronic social defeat).
Pharmacological models include withdrawal from psychostimu-
lant use. Lesion models include bilateral olfactory bulbectomy.
Genetic models include selectively bred lines (e.g. the Rousen
depressed mouse line, Flinders Sensitive Line rats, Wister Kyoto
rats, Fawn Hooded rats, SwLo/SwHi rats, cLH rat lines) (El
Yacoubi et al., 2003; Henn and Vollmayr, 2005; Overstreet and
Wegener, 2013; Rezvani et al., 2007; Will et al., 2003), and spe-
cific transgenic lines (e.g. 5-HT transporter knock-out rats and
mice, BDNF promoter IV-mutant mice, BDNF Met  mice) (Chen
et al., 2006; Sakata et al., 2010; Wisor et al., 2003). Their cogni-
tive/behavioral phenotypes such as anhedonia can be measured
using the sucrose preference test, conditional place preference,
intracranial self-stimulation, variable progressive ratio reinforce-
ment, and response bias probabilistic reword task; they can be
measures as negative processing bias using increased reactivity to
aversive stimuli, probabilistic reversal learning, and reactivity to
emotionally ambiguous cues. Some physiological endophenotypes
(e.g. sleep pattern changes) are recapitulated as well in these rodent
models.
Recently, stress vulnerability and depression susceptibility were
successfully decoded from large-scale electrophysiological record-
ings as distinct oscillation patterns in freely moving mice (Hultman
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modeling algorithm for multi-region LFP recordings (cross-spectral
factor analysis, CSFA). This algorithm breaks the observed signal
into factors defined by unique spatiotemporal spectral properties4 Y. Takeuchi, A. Berényi / Neuro
t al., 2018). The specific oscillation patterns for the vulnerability
nd susceptibility are consistent with the results of pharmaco-
ogical (interferon administration) and early life stress (maternal
eparation).
.1.7. Animal models for drug addiction
Animal models for drug addiction can be classified into
odels for the three stages: preoccupation/anticipation,
inge/intoxication, and withdrawal/negative affect stages (Koob
nd Volkow, 2010).
Animal models for the preoccupation/anticipation stage fit into
wo categories: extinction-based and abstinence-based relapse
odels (Venniro et al., 2016). Extinction-based relapse models
nclude drug-, cue-, context-, stress-, and withdrawal state-induced
elapses (Alleweireldt et al., 2001; Shaham et al., 2003), reac-
uisition (Bouton et al., 2012), and resurgence (Winterbauer and
outon, 2011). Abstinence-based relapse models include forced
bstinence and drug craving incubation (Fuchs et al., 2006), adverse
onsequences-imposed abstinence (Cooper et al., 2007), and volun-
ary abstinence induced by introducing non-drug rewards (Caprioli
t al., 2015). In addition, risky and gambling choice tasks and those
ith reward/aversion conflicts can be used to study the pathologi-
al oscillations underlying inappropriate, impulsive and executive
ecision making in addicted states (Passecker et al., 2019; Verharen
t al., 2018).
Animal models of the binge/intoxication stage consist of intra-
enous and oral drug self-administration (Ahmed and Koob, 1998),
ntracranial self-stimulation (Markou and Koob, 1992), conditional
lace preference (Sanchis-Segura and Spanagel, 2006), drug dis-
rimination (Stolerman et al., 2011), and genetic models of high
ddiction susceptibility (Quintanilla et al., 2006). In addition, the
rug taking in the presence of aversive consequences model can be
sed to find pathological oscillations governing compulsive drug
aking behavior (Vendruscolo et al., 2012).
Animal models of the withdrawal/negative affect stage include
ntracranial self-stimulation (reward decreases), conditional place
version (Hand et al., 1988), measures of anxiety-like responses
e.g. the open field and elevated plus mazes), and drug self-
dministration with extended access or in dependent animals
Ahmed et al., 2000).
.2. Neural activity recordings
.2.1. For animal research
Large-scale brain dynamics recordings as LFPs are very pow-
rful for investigating oscillatory activities across multiple brain
egions (Hong and Lieber, 2019; Pesaran et al., 2018). Beyond sin-
le site recordings, multi-site recordings with silicon probes have
llowed the geometry of oscillatory activities in the brain to be
tudied (Wise and Najafi, 1991). Linear 16–32 ch recording probes
ave been used to map  layer specific oscillations for example in
he cortex (Minlebaev et al., 2011). Recent CMOS-based probes
Neuropixel) enable up to 960 ch high-density recordings on a sin-
le shank (Jun et al., 2017). Multi-shank linear silicon probes (e.g.
uz256) can capture two-dimensional spatiotemporal structure of
scillations in a brain region (Agarwal et al., 2014; Berényi et al.,
014). For example, Oliva et al. found that sharp-wave ripple in the
A2 subregion precedes those in the CA1 and CA3 subregions in the
at HPC (Oliva et al., 2016).
The insertion of multiple silicon probes and/or wire electrodes
nto distinct brain regions allowed oscillatory interactions between
rain regions to be explored during spatial navigation (Fernández-
uiz et al., 2017), goal-directed behaviors (Fujisawa and Buzsáki,
011), epileptic seizures (Berényi et al., 2012), anxiogenic condi-
ions (Girardeau et al., 2017), depression (Hultman et al., 2018),
nd drug addiction (Sjulson et al., 2018). Matrix silicon probes cane Research 152 (2020) 87–107
be used to obtain high-density three-dimensional oscillation activ-
ities in the brain (Rios et al., 2016), and flexible mesh electronics
used instead of rigid electrodes enable year-long stable record-
ings (Hong et al., 2018). Two-dimensional electrodes on flexible
polymer sheets enable potential recordings from the cortical sur-
face (Khodagholy et al., 2015). Simultaneous recording of brain
and other physiological oscillations (e.g. electrocardiogram, elec-
tromyogram, and breathing) from freely-moving animals is an
important technique to study pathophysiological representations
of neuropsychiatric disorders (Sasaki et al., 2017).
3.2.2. For clinical practice
The international 10–20 or 10–10 EEG recording systems are
widely used for standard diagnosis or study of a variety of neu-
ropsychiatric disorders, including epilepsy (Nuwer et al., 1998).
One of the advantages of EEG recordings is its time resolution. This
enables fast oscillatory activities to be analyzed (typically 0.3–300
Hz). MEG  recordings have an even higher time resolution (in mil-
liseconds). The frequency spectrum density in each recording site
and the relationships between the recording sites (coherency, con-
nectivity, causality etc.) are typically analyzed. High-density EEG
recordings (64–256 ch) increase spatial resolution and allow source
imaging with even sub-lobar precision (Seeck et al., 2017). This
enables better spatial resolution for seizure focus prediction with
tomography. fMRI recordings give higher spatial resolution (in mil-
limeters) but lower time resolution (in seconds) compared to EEG
recordings; they primarily utilize the blood-oxygen-level depen-
dent contrast, which is complementary to EEG recordings. fMRI
recordings can be used to investigate very slow oscillatory activities
within and between brain regions. Invasive electrophysiological
recordings on or in the brain are required to find the seizure focus
much more precisely or the optimal location of DBS electrodes in
the basal ganglia of PD patients.
3.3. Machine learning-mediated approaches for analysis
It is challenging to find disease or disorder-specific oscillation
patterns in large-scale neuronal activity data. For example, unsu-
pervised learning techniques have been used to find significant
coherent resting-state fluctuations and functional connectivity of
resting-state fMRI data (Khosla et al., 2019). Unsupervised methods
like independent component analysis (ICA) and principal compo-
nent analysis (PCA) decomposition are also used to find latent
variable models in fMRI data. Deep learning methods such as
convolutional neural networks and feedforward neural networks
were used to successfully discriminate the fMRI data of AD and
schizophrenia patients from those of healthy control patients with
96.85 % and 85.8 % accuracy, respectively (Wen  et al., 2018). These
machine learning methods can also be applied for electrophysi-
ological data to find disease-specific oscillation patterns in EEG
or intracranial LFP data from humans and experimental animals
(Reardon, 2017). However, if the disease-specific oscillation model
is extracted by PCA, the model is so abstract that it cannot be
interpreted well enough to develop an intervention based on the
analysis.
Recently, Gallagher and others successfully developed a new(a power or cross-spectral densities) (Gallagher et al., 2017). The
critical thing is that the factors are interpretable. Combined with
a supervised-learning algorithm, CSFA has revealed symptom spe-
cific oscillation patterns in depression (Hultman et al., 2018).
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. Oscillopathy – the realistic view of pathological
scillatory states and a strategy for oscillotherapeutics
Here we describe the pathophysiology of oscillopathies with an
mphasis on epilepsy as a system of multistable dynamic oscil-
atory states. We  also provide a conceptual overview on how to
ntervene with pathological oscillations focusing on the control
f epilepsy and epileptic seizures in a time-targeted closed-loop
anner.
.1. Bistable or multistable circuit states
.1.1. Modelling concept and example of seizure model
Epilepsy is a network disorder which can be characterized by
istable or multistable oscillatory states (e.g. interictal and ictal
tates) and the transitions between them (Kalitzin et al., 2019).
ircuit-state dynamics are determined by the stability of each
tate and probability of transition between stable oscillatory states,
hich are supposed to be affected by the following factors: (1) net-
ork resonance, (2) resilience, (3) perturbation, sensory inputs (e.g.
 well-timed pulse input), (4) neuromodulatory inputs, and (5) time
pent in the state (Chang et al., 2018).
Stable oscillatory states include at least normal (interictal) and
ypersynchronous ictal states. This concept has been validated in
n vivo animal and human recordings and in silico modelling studies.
or example, theta frequency MS  stimulation stabilized oscillatory
ctivity in the septo-hippocampal axis and decreased seizure sus-
eptibility whereas over 20 Hz MS  stimulation induced transition
rom normal to ictal oscillatory state in rats (Fisher, 2015; Miller
t al., 1994). Modelling studies have successfully established realis-
ic behaviors of epileptic networks, which resemble network states
ncluding, normal states, pre-ictal recruitment, epileptic seizures,
nd post-ictal suppression (Bauer et al., 2017; Jirsa et al., 2014). The
eizure models can recapitulate oscillatory state transitions includ-
ng the onset, evolution, and termination of epileptic seizures. They
elp to explain mechanisms underlying the state transitions and
hey may  enable upcoming seizures to be predicted. They may  also
nable secondary generalization and possibly sudden unexpected
eath in epilepsy to be explained (Kuhlmann et al., 2018). Model-
ng studies have also explained the pathological oscillations of PD
Pavlides et al., 2015; Shouno et al., 2017).
.1.2. Generation of hypothesis and quantification of circuit states
Modelling studies are not merely explanatory tools but also an
nstrument to generate a hypothesis. They can also provide read-
uts of otherwise complex state indicators (Kalitzin et al., 2019). For
xample, CSFA (Gallagher et al., 2017), machine learning-assisted
odelling of multi-site oscillatory networks, has revealed previ-
usly unknown pathological oscillations for depression (Hultman
t al., 2018). In a multistate model study, the seizure susceptibility
f an instantaneous network state can be readout as a’ separatrix
roximity’ for the closeness to ictal transition (Petkov et al., 2018).
his is measure of instantaneous distance between the current net-
ork state and the threshold for the ictal (hypersynchronous state).
sing this possible biomarker of seizure susceptibility, epilepsy is
onsidered as a state where the average network oscillatory state
s close to the ictal threshold. Physicians or researchers can esti-
ate the effectiveness of treatments or new intervention technique
ith this biomarker. This strategy is quite effective for predicting
pcoming seizures, and for developing a new therapeutic technol-
gy in a very time-efficient manner. Seizure susceptibility is not
urrently titrated directly but estimated by seizure occurrence fre-
uency, which is time consuming and has high uncertainty due to
parseness. CSFA can be used instead to instantly quantify it once
he pathological pattern has been modelled; instantaneous amount Research 152 (2020) 87–107 95
of a disease-specific oscillation pattern is quantified as a spectral
factor score (Gallagher et al., 2017; Hultman et al., 2018).
Given the hypothesis and the quantitative measure of patho-
logical oscillatory network states, the following oscillotherapeutic
strategies would be effective to control epileptic seizures: (1) intro-
ducing oscillatory activity which resonates with and stabilizes
non-seizure states (e.g. theta oscillation in the HPC), (2) reducing
the normal to ictal transition rate by reducing seizure suscepti-
bility, especially during a seizure prediction period, (3) inducing
immediate transition from ictal to normal states by introducing
a huge oscillatory disturbance on ictal hypersynchronous oscilla-
tions, (4) intervening to prevent or any intermittent pathological
oscillations which would induce maladaptation in neural networks.
These strategies could be effective for intervening in other oscil-
lopathies with fast oscillatory state transitions, including PD and
possibly for the psychotic attack of schizophrenia, for impulsive
and addicted drug intake, and for an attack of PTSD.
For other oscillopathies with much slower underlying state
transitions (e.g. GAD, depression, addiction craving, and AD), long-
lasting plastic changes in oscillating network dynamics would be
required to be induced by external oscillatory interventions. For
example, on-demand deletion and the continuous introduction
of oscillations for negative and positive feelings might improve
depression symptoms.
4.2. Stimulation strategies
Pathological oscillations are intervened in an open- or closed-
loop manner in terms of how the stimulation is temporally
delivered. Intrinsic structure of the neuronal networks can be uti-
lized to maximize the effect of stimulation.
4.2.1. Open-loop interventions
Open-loop intervention in the oscillotherapeutic context means
introduction of external stimulation without the feedback of inter-
nal oscillatory activity (Fig. 2A). The external stimuli can be a
sinusoidal waveform or pulse trains. The open-loop intervention
can be non-invasive (e.g. transcranial electrical stimulation: TES)
or invasive (e.g. DBS). The open-loop stimulation with a sinusoidal
stimulus waveform can interact with ongoing intrinsic network
activities if appropriate stimulus intensity is provided (Fig. 2B). For
example, transcranially applied alternating electrical stimulation
can modify and entrain the membrane potentials of cortical neu-
rons in rats (Ozen et al., 2010). Furthermore, intense TES at 1 Hz
sinusoidal wave can phase-specifically enhance alpha-band activ-
ity in the parietal cortex of healthy human subjects (Vöröslakos
et al., 2018). If properly applied, these resonance approaches can
modulate the cognitive functions of humans (e.g. enhancement of
memory) (Hanslmayr et al., 2019; Reinhart and Nguyen, 2019). The
continuous application of high-frequency pulse trains to the STN
and the anterior nucleus of the thalamus (conventional DBS) suc-
cessfully improved symptoms of PD and drug-resistant epilepsy,
respectively (Deuschl et al., 2006; Li and Cook, 2018). However,
open-loop interventions are less flexible in terms of temporal struc-
ture compared with closed-loop interventions, which are discussed
below.
4.2.2. Closed-loop interventions
Closed-loop interventions for oscillotherapeutics are brain stim-
ulations based on intrinsic physiological signal feedback (e.g. LFP,
EEG) (Fig. 2A). The feedback information allows the stimulation to
be time-targeted and on-demand stimulation. It also avoids over-
stimulation and prevents unwanted out-of-phase interactions.
Closed-loop stimulation can reduce the side effects of exces-
sive and unnecessary stimulus delivery. Chronic stimulation in a
non-responsive, open-loop manner may  be unnecessarily exces-
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Fig. 2. Brain stimulation techniques for intervening with pathological oscillations.
(A) Schemas of open-loop and closed-loop interventions with epileptic seizures (pathological oscillation). Open-loop intervention provides pre-determined stimulus wave-
forms  without processing recorded brain activities (e.g. EEG). Recorded brain activities for closed-loop intervention are processed in rea-time, and the parameters of stimulus
waveforms (timing, intensity, frequency etc.) are determined online. (B) A schematic showing of sinusoidal stimulation in an open-loop manner and the typical responses of
neural  firing and intrinsic oscillations. Neural firings (spikes) and intrinsic oscillations are entrained to the externally applied stimulus frequency (resonance approach). (C)
Conceptual examples of closed-loop interventions for the destruction and restoration of intrinsic oscillations. Counter-phase stimulation (e.g. electrical stimulation) provides
the  opposite effect of intrinsic oscillation to destroy an arbitrary oscillation. In contrast, in-phase stimulation can restore decreased oscillation by enhancing the summation
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if  intrinsic oscillation. (D) A stimulation strategy for providing a widespread oscilla
rojections with fast synaptic transmissions (e.g. the medial septum). (E) A stimu
timulation of a bottleneck structure (choke point) of the internal oscillation can ef
ive. Unnecessary stimulation can introduce adverse effects by
isturbing physiological oscillations in the brain both by spatial on
nd off target effects. For example, chronic stimulation of the HPC
ay  disrupt normal physiological oscillation and thereby cognitive
unctions including learning and memory. Continuous strong elec-
rical stimulation on the scalp can introduce pain sensations via
eripheral nerve stimulation. In addition, chronic electrical stimu-
ation of the limbic structures (including the HPC and AMY) could
nduce pro-seizure effects called kindling (McIntyre and Gilby,
009). Importantly, an excessive continuous stimulus could induce
ccelerated habituation or rebound symptoms in patients (Pilitsis
t al., 2008; Shih et al., 2013). Patients instructed to turn on DBS in
n on-demand manner for essential tremor had longer effects than
pen-loop continuous stimulation (Kronenbuerger et al., 2006).Closed-loop stimulation could introduce much higher thera-
eutic effects for neurological and psychiatric disorders. The first
losed-loop configuration is ‘closed-loop responsive’ stimulation,
n which pre-determined stimulus pulses are delivered only whenffect externally by stimulating a target brain structure that provides diffuse axonal
 strategy for intervening with a huge internal oscillation (e.g. epileptic seizures).
ely intervene with it (e.g. the entorhinal cortex).
the stimulus is necessary (on-demand stimulation). In this con-
figuration, physiological signals are continuously monitored to
automatically trigger stimulation in an on-demand manner. For
on-demand control of epileptic seizures, we have revealed that
transcranial applied electrical stimulation triggered by electro-
graphically monitored seizures can effectively shorten the duration
of petit mal  seizures in rats (Berényi et al., 2012). The closed-
loop seizure suppression remained effective at least for months
(Kozák and Berényi, 2017). Responsive neurostimulation (the RNS
system) is approved for human application by the U.S. Food and
Drug Administration (FDA) as an adjunctive therapy for medi-
cally intractable partial seizure patients (Morrell, 2011). Seizure or
seizure-predicting neuronal activity is monitored via depth and/or
subdural strip leads and electrical stimulation is delivered through
these leads in an on-demand manner in the RNS system. For exam-
ple, HPC and cortical activities are monitored and intervened via
the depth and strip leads, respectively. Closed-loop responsive
stimulation can be controlled by behavioural oscillations as well.
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oganemaru and others have reported that walking rhythm trig-
ered TES of the primary motor cortex in stroke patients could
mprove their gain disturbance (Koganemaru et al., 2019).
The second closed-loop configuration for brain stimulation
s ‘closed-loop adaptive’ stimulation, in which input physiologi-
al variables gate output variables for stimulation. For example,
he power of beta oscillation in STN LFP determines the inten-
ity of DBS on the STN for PD patients (Bouthour et al., 2019).
he relationship between input and output variables is fixed or
rogramable. Adaptive closed-loop brain stimulation has been
uggested for controlling neurological and psychiatric disorders
epilepsy, movement disorders, AD, depression, and obsessive-
ompulsive disorders) (Hoang et al., 2017; Provenza et al., 2019).
The third important nature of closed-loop stimulation is ‘phase-
argeting’ stimulation. Theoretically, phase-targeting electrical
timulation is very effective in the destruction of pathological oscil-
ations and in the restoration of reduced physiological oscillations
Fig. 2C). Counter-phase stimulation destructs pathological oscil-
ations and in-phase stimulation restores reduced physiological
scillations. Practically, precisely-timed phase-targeting stimulus
elivery over ongoing pathological oscillations has been proved
o be essential for the closed-loop intervention of epilepsy and
D (Berényi et al., 2012; Holt et al., 2019). In addition, HPC LFP
hase-specific fornical stimulation has been proposed to improve
he cognitive functions of AD patients (Senova et al., 2018). This
s because temporal organization of theta and gamma  oscillations
n the HPC are thought to be important in memory encoding and
etrieval (Colgin, 2016). Dejean and others have shown that the
hase-specific optogenetic excitation of PV-positive interneurons
n the PFC over frontal 4 Hz oscillation bidirectionally controls fear
ehavior of auditory cue conditioned mice (Dejean et al., 2016).
.2.3. How to effectively introduce or disturb oscillatory activities
Introducing or disturbing oscillatory brain activities in an effec-
ive way is essential for oscillotherapeutics. Utilizing intrinsic
ircuit structures in the brain is an important factor for effec-
ive interventions. Stimulation of a hub-like structure is effective
pon introducing widespread oscillatory activity into the brain
Fig. 2D). If the target brain region has diverging projections to sev-
ral destination brain regions, oscillatory activity applied to the
arget region can spread to the destination brain regions via axonal
rojection and synaptic transmissions. The applied stimulation fre-
uency should be within the frequency properties of the neuronal
ircuits. For example, the MS  is in the midline of the basal fore-
rain and projects to the bilateral HPC in a diverging way. This
athway is mainly mediated by fast GABAergic synaptic transmis-
ions (Dutar et al., 1995). The MS  and HPC are highly coherent in
oth physiological and pathophysiological conditions. The electri-
al or optogenetical stimulation of the MS  is transmitted to the
ilateral HPC at exactly the same frequency that is applied within
he delta to gamma-band range (Sinel’nikova et al., 2009; Zutshi
t al., 2018). For human application, the thalamic stimulation for
efractory epilepsy, the fornical stimulation for AD, and the medial
orebrain bundle stimulation for depression all utilize this principle
or DBS (Dandekar et al., 2018; Li and Cook, 2018; Mirzadeh et al.,
016). In addition, both TES and transcranial magnetic stimulation
TMS) of the PFC for treatment of depression and drug addiction
lso utilize this principle, because the PFC has widespread synap-
ic connections to the limbic brain structures (Ferenczi et al., 2016;
oo et al., 2012; Noda et al., 2017).
The intervention of a bottle-neck relay station in the brain is
ffective for intervening with the propagation of huge oscillatory
ctivity like epileptic seizures. For example, partial seizures in the
PC occasionally secondary generalize, which may  be a cause of
udden unexpected death in epilepsy (SUDEP) (Bone et al., 2012;
assey et al., 2014). The subiculum and the entorhinal cortex are Research 152 (2020) 87–107 97
bottleneck structures (choke points) from the HPC to the neocor-
tex. Interventions on these structures can effectively suppress the
secondary generalization of HPC-origin seizures (Lu et al., 2016;
Wang et al., 2017). The thalamus and the STN are choke points in
post-stroke epilepsy and absence epilepsy, respectively (Paz and
Huguenard, 2015).
5. Oscillotherapeutics – embodiment for distinct
modalities
Here we  provide an overview of several brain stimulation
technologies with different modalities that can be employed for
oscillotherapeutics. In addition to the time-targeting nature of
closed-loop configurations, brain stimulation technologies offer
space-targeting. Combining less aversive time- and space-targeting
enables oscillotherapeutics to provide therapeutic options distinct
from pharmacological treatments, which are easier in terms of
their application but have sustained and off target effects. We
discuss deep brain stimulation (DBS), transcranial electrical stimu-
lation (TES), transcranial magnetic stimulation (TMS), transcranial
focused ultrasound stimulation (tFUS), and optogenetic stimulation
for the space-targeting.
5.1. Deep brain stimulation
The main advantages of DBS for oscillotherapeutics are its focal-
ity and efficacy (Kringelbach et al., 2007). Stimulus leads are directly
inserted into the brain. Electrical stimulation can be limited to
the target structure and the stimulation energy directly activates
nearby neurons and axonal fibers without shunting via the skull.
However, one of drawbacks of DBS is its invasiveness. There are
risks of infection and bleeding because of the electrode insertion.
Although DBS is basically reversible, the insertion causes microle-
sion along the electrode track from the surface to the target region.
Thus, if the target region is superficial, transcranial stimulation may
be considered.
DBS electrodes are precisely located with stereotaxic surgery
while stimuli are delivered to validate its effects on symptoms
especially for motor disorders. DBS stimulation can be provided
in a closed-loop responsive manner to achieve time-targeting
(Bouthour et al., 2019). DBS stimulations are usually provided as
pulse trains and they can be delivered chronically, intermittently,
or precisely synchronized with electrophysiological or behavioural
signals in a closed-loop manner. The stimulus parameters include
frequency, pulse width, pulse amplitude etc. These parameters
have been titrated by physicians empirically, but they can be guided
by pre-clinical studies using optogenetics (Creed et al., 2015). The
stimulation parameters can be updated online using closed-loop
adaptive techniques. For example, dynamic changing of amplitude
in response to beta-band power in the STN for PD (Bouthour et al.,
2019; Provenza et al., 2019). DBS has already been used for PD,
drug-resistant epilepsy, treatment resistant depression, and drug
addiction (Deuschl et al., 2006; Li and Cook, 2018). DBS for AD,
schizophrenia, GAD, and PTSD are under investigation (Bina and
Langevin, 2018; Krack et al., 2010). DBS acts rapidly for movement
disorders but it takes time for depression treatment.
5.2. Transcranial electrical stimulation technologies
TES is a non-invasive brain stimulation technique. It is a safe and
reversible adjunctive therapy because its stimulus electrodes are
located outside the skull. TES technologies are classified into ECT
and non-convulsive therapy. Although ECT on the PFC is one of the
effective therapies for depression (and is still used for schizophre-
nia in developing countries), we focus here on non-convulsive TES.
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his is because of its therapeutic potential for the on-demand con-
rol of many symptoms of neurological and psychiatric disorders,
ombined with closed-loop time-targeting nature. The focality of
ES is not as good as DBS or TMS  because of its transcranial nature.
owever, its diffuse mild modulation over the cortex may  be an
dvantage for intervention (e.g. desynchronization) of pathologi-
al oscillations in widespread cortical regions for example absence
eizures (Berényi et al., 2012; Kozák and Berényi, 2017). Further-
ore, the focality of TES has improved via recent advances in the
echnologies we discuss below. Traditionally, the stimulus inten-
ity of non-convulsive TES has been limited to up to 2 mA and it
as been used for neuromodulation.
However, we recently found that this amount of stimulus inten-
ity is not enough to directly induce large enough electrical fields
1 mV/mm)  that in turn reliably induce action potential in the
ntracranial space, because of the shunt effect of the skull and skin
Liu et al., 2018). Thus, we have developed a new TES technology
Intersectional-Short Pulse (ISP) stimulation) by which electrical
timulation can be transcranially focused in any intracranial space,
nabling much higher electrical currents (Vöröslakos et al., 2018).
earable or implantable devices for closed-loop, focused TES inter-
ention will be available in the future because TES device can be
mplemented in smaller devices than TMS  and tFUS technologies
see Section 6).
.2.1. High definition transcranial direct current stimulation
tDCS is used for inducing plastic changes by introducing sub-
hreshold membrane potentials in the neurons in the cerebral
ortex. Classical tDCS employs two large electrodes (25–35 cm2)
or the stimulation. tDCS induces subthreshold depolarization of
ortical neurons below the anodal electrode, and hyperpolarization
elow the cathodal electrode. Repeated tDCS conducted once a day
or five or more consecutive days, can induce long-lasting effects on
otor performance, depressed mood, and other functions for one
onth or more after stimulation (Buch et al., 2017; Loo et al., 2012).
fforts have been made to increase the focality of tDCS by reducing
he size of the relatively large stimulus electrode placed over the
arget area, by increasing the size of the return electrode, and/or
y placing the return electrode at another location other than the
calp (for example, the neck, shoulder, and arms, or knee).
Alternatively, an electrode configuration has been developed to
ptimize stimulation focality on the basis of the modelling of elec-
rical field strength. The so-called high definition tDCS (HD-tDCS)
s one of these approaches (Nitsche et al., 2015). Relatively small
lectrodes are placed in the vicinity of the stimulation electrode
or this approach (Datta et al., 2009). Since the distance between
he respective electrodes is relatively short, shunting is enhanced
elative to the more conventional electrode arrangements. There-
ore, current density has to be relatively high to obtain similar
ffects as large electrode pads. Studies have revealed that HD-tDCS
reatment has alleviated symptoms of epilepsy and pain perception
Castillo-Saavedra et al., 2016; Meiron et al., 2019).
.2.2. High definition transcranial alternating current stimulation
Transcranial alternating current stimulation (tACS) is relatively
 newly developed stimulation technique that non-invasively
odulates cortical excitability and activity. While tDCS induces
europlasticity via the constant polarization of neuronal mem-
rane potentials with the application of a tonic subthreshold direct
urrent, tACS is thought to affect neuronal membrane potentials by
scillatory electrical stimulation with a specific frequency (Nitsche
t al., 2015). The stimulation used for tACS and its duration are
uite similar to tDCS. tACS at a normal stimulus frequency (1–100
z) does not induce any plasticity but it interacts with the intrinsic
scillatory activities in the brain (Antal et al., 2008). However, tACSe Research 152 (2020) 87–107
at a much higher frequency (140 to low kHz range) may  induce
neuroplastic excitability alterations (Antal et al., 2017).
Recently, a new tACS configuration has emerged, the so-
called high-definition (HD-tACS). Stimulus focality is dramatically
increased in HD-tACS via having one stimulating electrode on
the target structure surrounded by several anti-phase returning
electrodes. Several cortical regions can be independently stimu-
lated with distinct oscillatory stimulus waveforms by using this
stimulation technology. Reinhart has artificially synchronized and
desynchronized the human medial frontal cortex and the lateral
PFC in theta-band frequency, and successfully modulated execu-
tive functions using HD-tACS stimulation (Reinhart, 2017). Reinhart
and Nguyen also found that the forced coupling of the PFC and
the temporal cortex in theta frequency improved working memory
task performance in aged adults (60–76 years of age) (Reinhart and
Nguyen, 2019). HD-tACS can be delivered in a closed-loop manner.
5.2.3. Temporal interference stimulation
Temporal interference (TI) stimulation is a newly developed TES
technique that enables deep brain stimulation without electrode
insertion (Grossman et al., 2017). TI stimulation utilizes the tem-
poral interference between two  electrical fields with alternating
vectorial directions in similar but slightly different, over-kilo Hertz
frequencies. For example, Grossman and others applied 2 kHz (f1)
and 2.01 kHz (f2) alternating current stimulations on the heads of
mice. Depending on the alignment of the electrodes, the super-
position of the two electric fields inside the brain resulted in an
electrical field at the average frequency of f1 and f2, whose enve-
lope was  modulated at the frequency of delta f (10 Hz). The 10 Hz
modulated envelope entrained the action potentials of the neurons
inside the brain, whereas the very high frequency oscillating (>2
kHz) electrical fields did not cause any changes in the membrane
potentials of cortical neurons because of intrinsic low-pass filter-
ing properties of the neuronal membrane. They also showed that
TI stimulation could transcranially induce cFos (immediate early
gene) expression in the hippocampal neurons of mice, but not in
neurons in the overlaying cortex.
The TI stimulation is an innovative technique, but only its
proof of concept has been established so far, especially because
it does not address the bottleneck of intensity dependent periph-
eral side-effects establishing its efficacy with non-human primates
or healthy human volunteers is required before possible clinical
application. The spatial resolution and maximal depth for effective
stimulation will be dependent on the number and alignment of
electrodes on the scalp. One issue could be the possible off-target
effects of very high frequency electrical fields over large brain areas.
Strong kHz-frequency electrical fields can block the propagation
of compound action potential in peripheral nerves (Kilgore and
Bhadra, 2014). In their experiments, the 2 kHz electrical stimulation
with hundreds microampere order did not induce any acute physi-
ological effects on the brain. Further experiments will be necessary
for determining the upper limit of the electrical field to ensure
that any conduction block on axons in the brain is not induced.
Chaieb and others have reported that very high frequency electri-
cal fields (1–5 kHz) could induce neural plasticity similar to that
which can be evoked by anodal direct current stimulation (Chaieb
et al., 2011). The long-term effects of kHz stimulation of TI should
be studied in future. Temporal resolution of TI simulation has a
limitation because the introduction of kHz electrical fields in short
ramp-up times induces the transient non-spatially focused activa-
tion of neurons, whereas slow ramp-up does not. Because of this
limitation, closed-loop TI with time precision (e.g. phase-targeting
stimulation) is not feasible. Therefore, TI stimulation seems prefer-
able to applications for inducing plasticity in non-cortical deep
brain regions.
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.2.4. Intersectional short pulse stimulation
We have recently developed a new TES technology, by which
timulus induced electrical fields can be focused in any region of the
rain (Vöröslakos et al., 2018). The spatially-targeted TES has been
chieved by spatiotemporally rotating Intersectional Short Pulse
ISP) stimulation (2.5–10 s duration, 5–50 s pause, depending
n the number of electrode pairs) (Fig. 3A). This method exploits
he integration time constant of the neuronal membrane (5–20 ms),
 mechanism that can temporally integrate multiple consecutive
lectrical gradients with similar vector directions (Fig. 3A). Because
f this, ISP stimulation could transcranially focus a strong enough
lectrical field on a target brain region to directly induce or inhibit
ction potentials (> 1 mV/mm)  without placing too much current
ensities on the scalp (i.e. it is less painful). Spikes of HPC neurons
ould successfully be modulated in a hemisphere specific manner
ith ISP stimulation. Furthermore, the 1 Hz ISP stimulation phase-
nd hemisphere-specifically modulated amplitude of alpha-band
ctivities of EEG in healthy volunteers.
The major advantages of ISP stimulation are: (1) Focality. ISP
timulation can focus on a small brain region. This focus can
e further improved by placing a number of electrode pairs on
he scalp; (2) Time-resolution. It can be easily implemented with
 closed-loop configuration with millisecond precision. Phase-
argeted closed-loop stimulation is possible; (3) Intensity. Currents
s high as ten-sixteen mA  can be used (an order of magnitude larger
han conventional TES) because the current density on each elec-
rode is similar to that of conventional TES; (4) Bilateral stimulation.
he same effects (excitation or inhibition) can be applied on both
emispheres simultaneously by aligning electrodes (unlike con-
entional TES, which induces opposing anodal-cathodal effects).
his is because direction of electrical fields along dendrite-axon
xis on neurons determines whether the electrical fields acti-
ate or inhibit the target neurons (Liu et al., 2018), and ISP can
nduce symmetrically directed electrical fields on the both hemi-
pheres (Fig. 3B); (5) Versatility. Several distinct stimulus waves
an be employed independently for example to introduce distinct
timulus phase difference to different brain regions (Fig. 3B). ISP
timulation can be combined with tDCS, tACS, and even TI stimu-
ation in principle; and (6) Simplicity. The ISP stimulation device
an easily be miniaturized to be implantable or wearable. This
nables the long-term control of neurological and psychiatric dis-
rders, even for domiciliary care (Fig. 4B). ISP stimulation could
nable non-invasive on-demand closed-loop control with space-
nd time-targeted brain stimulation for neurological and psychi-
tric disorders.
.3. Transcranial magnetic stimulation
TMS  is non-invasive brain stimulation technique that has
een used for modulating symptoms of depression, schizophrenia,
ddiction etc. (Diana et al., 2017; Farzan et al., 2012; Fox et al., 2012).
MS  employs the principle of electromagnetic induction, in which a
hanging magnetic field gives rise to a companion electric field that
nduces electric currents in nearby conductive structures (Hamada
nd Rothwell, 2015). A large pulse of current in the external stimu-
ating coil generates a rapidly changing magnetic field that rises to
and falls from) 1 T or more within 1 ms.  The design of the external
timulating coil affects the distribution of the induced field in the
rain; the spread and depth of conventional figure-8 stimulating
oils are 5 cm2 and 1.0–3.5 cm,  respectively (Deng et al., 2013). The
ain target of TMS  is the cortex, but H-coil and double cone coils
lso enable the stimulation of deeper structures.
The main advantage of TMS  is its high titer stimulation. Its
nducted currents in the intracranial space are strong enough to
irectly evoke the action potentials of cortical neurons without
esonance (stimulation of the motor cortex can evoke muscle Research 152 (2020) 87–107 99
movements). rTMS of the PFC achieves better or comparable effi-
cacy than ECT for depression and it has less cognitive side effects.
The time-resolution of TMS  is good enough to be combined with
closed-loop configurations. Major drawbacks of TMS are its cost
and size. Due to the physical constrains of coil size, TMS  instru-
ments cannot be implanted or wearable. TMS treatments can only
practically be possible in hospitals.
5.4. Transcranial focused ultrasonic stimulation
Low-intensity tFUS is an emerging brain stimulation technology
that modulates mammalian brain activity (Fomenko et al., 2018).
Relatively low intensity (<3 W/cm2) and low frequency (0.25–0.5
MHz) ultrasound stimulation is used for human neuromodula-
tion studies. Stimulation parameters (e.g. sonication duration) and
intensity determine whether a stimulus has excitatory or inhibitory
effects. The mechanisms by which low-intensity ultrasonic stimu-
lation modulates neuronal activity have been poorly understood.
Thermal and non-thermal mechanisms have been proposed, but
thermal mechanisms are negligible because low-intensity tFUS
does not cause a significant rise in tissue temperature during
sonication (<0.1 ◦C). Direct effects on neuronal membrane and
ion channels have been suggested as non-thermal mechanisms
(Plaksin et al., 2014).
The major advantage of tFUS is its focality even for deep brain
structures (however, compensation of bone scattering is challeng-
ing). Human and non-human primate studies have shown that the
stimulus focus can be as small as 2–5 mm and tFUS can focus on
(for example) the basal ganglia without affecting the cortex (Legon
et al., 2014). In addition, tFUS can be delivered in a closed-loop
manner (Fig. 4A). Miniaturization of the transducer and amplifier
will be required for implantable or wearable devices. Implantable
transcranial ultrasonic devices for mice have been reported, but
none for humans yet (Li et al., 2019). tFUS can transiently open the
blood brain barrier and it can be used for both time- and space-
targeted drug delivery for the central nervous system following
intravenous administration of nanoparticle- or microbubble-caged
drugs (Landhuis, 2017).
5.5. Optogenetics
Optogenetics is an innovative technology for the cell-type-
specific manipulation of neuronal excitability with millisecond
precision. Causal relationships between neuronal activities and
natural behaviors have been extensively explored in neuroscience
fields using optogenetics (Grosenick et al., 2015). The major
advantages of optogenetics as a brain stimulation technique
come with the genetically coded nature of its actuators (opsins).
This genetic nature combined with various promoters and viral
vector-mediated gene transduction enables cell-type- and neural
pathway-specific, and even activity-dependent opsin expression
in arbitrary brain regions (Kim et al., 2017). Opsin expression
can be pharmacologically controlled via the Cre-estrogen recep-
tor or Tet on/off system. The manipulation of neuronal excitability
can be bidirectional with fine temporal resolution. For example,
channelrhodopsin-2 and iC++ can respectively be used for blue
light-mediated excitation and inhibition with millisecond preci-
sion.
The pathophysiology of neurological and psychiatric disor-
ders and possible intervention strategies for them have been
explored using animal models with closed-loop optogenetics.
For example, Krook-Magnuson and others showed that seizure-
triggered on-demand optogenetic inhibition of HPC pyramidal
neurons suppresses HPC electrographic seizures in mice (Krook-
Magnuson et al., 2013). Carlson and others showed that cortical
slow oscillation-timed gamma  frequency optogenetic activation of
100 Y. Takeuchi, A. Berényi / Neuroscience Research 152 (2020) 87–107
Fig. 3. Intersectional Short Pulse stimulation: a focused transcranial electrical stimulation technology.
(A)  Principle of Intersectional Short Pulse (ISP) stimulation. Multiple anodal and cathodal electrode pairs are located on the skull or scalp. Electrical stimulation was temporally
interleaved at 5–25 s and rotated within the electrode pairs. The electrical field generated by the stimulation is focused to an arbitrary region of the brain. (B) Expansion of
ISP  technology for multiple focusing points with two distinct stimulus waveforms (green and magenta in the left). Depending on electrode alignment and stimulus polarity,
multiple brain regions can be stimulated using distinct stimulus waveforms causing the same effect (excitatory or inhibitory) on both hemispheres (right). Green and magenta
arrows  indicate current flows from anode to cathode. Black arrows indicate phase differences (temporal shifts) between the distinct stimulus waveforms.
Fig. 4. Future direction and engineering challenges.
(A) Pre-clinical research and development of closed-loop interventions for neurological and psychiatric disorders in the near future. Efficient algorithms should be developed
for  real-time detection of specific pathological oscillation patterns with large-scale data streams. Several brain stimulation modalities (e.g. electrical, ultrasonic, and optical)
a rable 
T EG (rs
u evice
t
m
bre  investigated for efficient transcranial stimulation. (B) The development of wea
he  real-time decoding of specific features of chronic symptoms from resting state E
nits will be necessary for faster computation and lower power consumption. The dhe PFC to thalamic pathway alleviated depression-like behavior in
ice (Carlson et al., 2017). Major drawbacks of optogenetics as a
rain stimulation technique for humans are gene introduction anddevices for the closed-loop intervention of neurological and psychiatric disorders.
-EEG) will be much more demanding on computation. Parallelization of processing
s need to be miniaturized to become wearable or implantable.invasiveness. Virus-mediated gene transduction and the insertion
of optical fibers into the brain is not easily justified in terms of risk
versus benefit. Magnet or radio-wave sensitive genetically coded
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ctuators may  enable the transcranial manipulation of defined neu-
al circuits without optical fiber insertions, but gene manipulation
s still required. However, Optogenetics is a very powerful and use-
ul technique for basic oscillopathy research.
. Engineering challenges and future directions
In addition to the pathophysiological aspects of oscillopathies
nd brain stimulation technologies themselves, technical imple-
entation challenges the clinical applications of closed-loop brain
timulation should be addressed. Here we focus on the challenges of
mplementing closed-loop ISP stimulation for the real-time control
f refractory epilepsy and beyond.
.1. Recording and real time processing of pathological
scillations
Pathological oscillations need to be intervened in real-time for
he online control of neurological and psychiatric disorders. At basic
esearch levels, we previously developed an analog electrical circuit
ystem for the real-time detection and phase-specific intervention
f epileptic seizures (Berényi et al., 2012). This system is very fast
nd has virtually no delay. However, an analog electrical circuit
ystem is not flexible enough to be the best solution for develop-
ng new algorithms or even for tuning the detection parameters of
xisting algorithms. Analog electrical circuit systems are not even
ize efficient.
Therefore, we have developed a digital seizure detection system
sing a real-time digital signal processor unit and a 256 ch multi-
lexed biosignal amplifier (Berényi et al., 2014; Kozák and Berényi,
017). Harnessing its 100 MHz  digital signal processors (DSPs), we
ould implement a 24 h real-time closed-loop TES system with
p to eight subjects (rats). Each subject has 30 ch recording sites.
he time resolution of the system is 2 ms,  but it is configurable
ith a trade-off between the number of recording sites and the
umber of calculations for each subject. The graphical programing
nvironment for the system enabled us to utilize many digital sig-
al processing functions (arithmetic, filtering, root-mean-square,
ower spectrum and coherency calculation, timer, counter, logic
ates etc.) to implement virtually any simple detection algorithm
rom multi-dimensional time series. While a closed-loop control
rogram is running in the system, any parameters in a detection
rogram can be turned via any external programming environ-
ent that supports ActiveXTM controls including MATLAB, Visual
asic, Visual C++, LabView, Python etc. Other groups have also
eported seizure detection systems; for example, Armstrong and
thers reported a MATLAB-based system (Armstrong et al., 2013).
he Open Ephys-based closed-loop system is also getting popu-
ar in field in systems neuroscience (Siegle et al., 2017). There is
ome intervention delay for closed-loop in the system because sig-
al processing calculations are conducted in the host PC. They are
ependent on the data transfer speed of serial ports (means of 11 ms
ia USB2.0 and 8 ms  via USB3.0). This delay is planned to be reduced
o be less than 1 ms  by developing a PCIe acquisition board in future
https://open-ephys.atlassian.net/wiki). Phase-locked (targeting)
timulation is essential for efficient intervention in pathological
scillations. New algorithms (for instantaneous phase-calculation,
or example) will be useful and can be implemented in the above
entioned closed-loop system for efficient pathological oscillation
ntervention (Mansouri et al., 2017).
The real-time prediction of seizures is more demanding thanetecting seizures themselves because of smaller signal-to-noise
atios and untypical feature changes, but prediction is more valu-
ble than detection as it enables prevention (Kuhlmann et al., 2018).
ecruiting larger number of time series data for analysis, calcu- Research 152 (2020) 87–107 101
lating coherence or causality matrices, entropy, phase-amplitude
coupling, and/or loss of resilience could all be useful to increase
detection power and decrease false positive detections. They could
enable the detection of a seizure predictor specific network activity
pattern as three-dimensional template matching (Fig. 4A) (Chang
et al., 2018). The real-time detection of the symptom-specific
network activities of psychiatric disorders can be as (or more)
demanding as seizure prediction because its oscillatory represen-
tations are not supposed to be as evident as epileptic seizures. They
are typically subtle and distributed to many brain regions (Fig. 4B)
(Carlson et al., 2017; Hultman et al., 2016, 2018). This means that
much faster algorithm and computation may  be required for psy-
chiatric disorders than for epilepsy.
Another possible issue related to interventions for predicted
seizures and psychiatric disorders is that their specific oscillatory
patterns are so complex. It would not be very efficient to find these
patterns via exploratory analyses by the researchers themselves. As
we have already discussed earlier in this paper, machine learning-
mediated modelling of oscillatory network activities (e.g. CSFA)
would be useful to identify them instead. Although precise offline
modelling is a time-consuming process even with powerful com-
puters, online detection of specific oscillatory patterns based on
the established model (real-time brain state classification) would
be feasible because it does not require intensive calculations as the
modelling process. A reduction in the dimension and complexity
of the established model may  be required for online intervention.
Superfast, massively parallelized graphical processing unit (GPU)
computing would be useful to implement real-time online closed-
loop interventions for research purposes.
6.2. Stimulation: precise localization for targeting a seizure (or
symptom) focus in the brain
Increase of number of pairs of stimulus electrode pairs is
important for further improvement of spatial resolution of ISP
stimulation (and this is the case for TI stimulation and tFUS as
well). A specialized headset with multiple EEG and stimulus elec-
trodes is required for transcranial closed-loop intervention with
ISP stimulation (Fig. 4B). Intracranial implantation of the stimu-
lus electrodes will increase the efficacy and focality at the expense
of non-invasiveness. The alignment of stimulus electrodes should
be tailored for the individual needs of each patient, especially for
focal seizures. The target brain region should be determined via
high-density EEG-mediated functional tomography and the long-
term video monitoring of seizures. Brain structure imaging will be
also required for designing of the ISP stimulation target. Although
electrical artifacts of ISP stimulation are smaller than those of con-
ventional TES, feedforward removal of gross artifacts from applied
currents is required (Kohli and Casson, 2019; Vöröslakos et al.,
2018). Ready-to-use simulation environments for electrode align-
ments and artifact predictions should be developed for the clinical
application of ISP stimulation.
The optimization of stimulation parameters (stimulus fre-
quency, duration, intensity etc.) is critical for alleviating symptoms
effectively. This optimization has been conducted by physicians
empirically, but it is time-consuming. Deep learning technology
is suggested to find optimal DBS stimulus parameters for move-
ment disorders for the effective real-time classification of brain
states (a closed-loop intelligent implementation of adaptive DBS)
(Neumann et al., 2019). This approach could be implemented
in future for optimizing closed-loop ISP stimulation to control
epilepsy and psychiatric disorders as well. Supervised and rein-
forced learning would be useful for initial parameter settings and
dynamic optimization during ongoing intervention treatments,
although artificial intelligence (AI) medicated brain stimulation is
currently cleared by the FDA
1 scienc
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.3. Device implementation- miniaturization, power supply, and
oT in the 5 G era
The implementation of ISP stimulation for implantable or wear-
ble devices requires the miniaturization of each unit for recording,
rocessing, and stimulation, which we are working on. Detection
lgorithms should be simplified and optimized to be implemented
nto a micro processing unit for example a field-programmable gate
rray (FPGA), although it requires low-level programming skills of
xperienced engineers. Massive parallelization will be required to
nsure real-time computation in a small device with limited clock
ate without significant delay. This will also improve power effi-
iency (Hirano et al., 2015). The use of bionic chips optimized for
achine learning with neuronal data (Qiao et al., 2015) would be
seful for much faster mobile devices as implemented in iPhone X
Apple A11) or Intel’s Nervana Neural Network Processors. Even
uantum computing processors (e.g. Google’s Sycamore proces-
or) might be implemented in medical devices in the future (Arute
t al., 2019). Many implantable or wearable medical devices will be
lways connected via the Internet of Things (IoT) in the 5 G or 6 G
ra. They will have large highly reliable data transfer capabilities
ith negligible delay. Computation for closed-loop interventions
ay be outsourced to external supercomputer servers via highly
eliable bidirectional data streams in those eras. The power supply
or implantable or wearable devices needs to be addressed. Minia-
urized rechargeable batteries with large capacities are required.
ontactless recharge stations (via magnetic induction for exam-
le) may  be available everywhere in the future at least in big cities
Mickle et al., 2019).
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